Search for other papers by Yuan Fang in
Google Scholar
PubMed
Search for other papers by Xuehong Zhang in
Google Scholar
PubMed
Search for other papers by Huilin Xu in
Google Scholar
PubMed
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
Search for other papers by Stephanie A Smith-Warner in
Google Scholar
PubMed
Search for other papers by Dongli Xu in
Google Scholar
PubMed
Search for other papers by Hong Fang in
Google Scholar
PubMed
Search for other papers by Wang Hong Xu in
Google Scholar
PubMed
Introduction Type 2 diabetes (T2DM) has been associated with an elevated risk of liver, pancreas, endometrium, colorectal, breast and bladder cancers and a decreased risk of prostate cancer ( 1 , 2 ). Several possible mechanisms have been
Search for other papers by Clara Lundetoft Clausen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Trine Holm Johannsen in
Google Scholar
PubMed
Search for other papers by Linda Maria Hilsted in
Google Scholar
PubMed
Search for other papers by Niels Erik Skakkebæk in
Google Scholar
PubMed
Search for other papers by Pal Bela Szecsi in
Google Scholar
PubMed
Search for other papers by Lise Pedersen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Thomas Benfield in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
(IL1A/IL-1F1); IL1B (IL-1 beta/IL-1F2); IL-1 receptor antagonist (IL-1ra/IL-1F3); IL2; IL3; IL4; IL5; IL6; IL7; IL8 (CXCL8); IL10; IL12p70; IL13; IL15; IL17 (IL-17A); IL17E (IL25); IL33; programmed death-1 ligand 1 (PD-L1/B7-H1); platelet
Search for other papers by Christin Krause in
Google Scholar
PubMed
Search for other papers by Martina Grohs in
Google Scholar
PubMed
Search for other papers by Alexander T El Gammal in
Google Scholar
PubMed
Search for other papers by Stefan Wolter in
Google Scholar
PubMed
Search for other papers by Hendrik Lehnert in
Google Scholar
PubMed
Search for other papers by Oliver Mann in
Google Scholar
PubMed
Search for other papers by Jens Mittag in
Google Scholar
PubMed
Search for other papers by Henriette Kirchner in
Google Scholar
PubMed
, ranging from steatosis with normal hepatic function to nonalcoholic steatohepatitis (NASH) and further to cirrhotic NASH and even hepatocellular carcinoma (for review see ( 1 )). Several endocrine pathways are known to contribute to the development and
Search for other papers by C Sui in
Google Scholar
PubMed
Search for other papers by Q He in
Google Scholar
PubMed
Search for other papers by R Du in
Google Scholar
PubMed
Search for other papers by D Zhang in
Google Scholar
PubMed
Search for other papers by F Li in
Google Scholar
PubMed
Search for other papers by G Dionigi in
Google Scholar
PubMed
Search for other papers by N Liang in
Google Scholar
PubMed
Search for other papers by H Sun in
Google Scholar
PubMed
sampled LNs, size of the largest positive LN, size of the largest metastatic focus within a LN, and lymph node ratio (NR)) were considered as potential prognostic factors ( 1 ). The size and number of positive LNs have been included in the risk
Search for other papers by Avinaash Maharaj in
Google Scholar
PubMed
Search for other papers by Ruth Kwong in
Google Scholar
PubMed
Search for other papers by Jack Williams in
Google Scholar
PubMed
Search for other papers by Christopher Smith in
Google Scholar
PubMed
Search for other papers by Helen Storr in
Google Scholar
PubMed
Search for other papers by Ruth Krone in
Google Scholar
PubMed
Search for other papers by Debora Braslavsky in
Google Scholar
PubMed
Search for other papers by Maria Clemente in
Google Scholar
PubMed
Search for other papers by Nanik Ram in
Google Scholar
PubMed
Search for other papers by Indraneel Banerjee in
Google Scholar
PubMed
Search for other papers by Semra Çetinkaya in
Google Scholar
PubMed
Search for other papers by Federica Buonocore in
Google Scholar
PubMed
Search for other papers by Tülay Güran in
Google Scholar
PubMed
Search for other papers by John C Achermann in
Google Scholar
PubMed
Search for other papers by Louise Metherell in
Google Scholar
PubMed
Search for other papers by Rathi Prasad in
Google Scholar
PubMed
Lovric (3) 29 † c.1049A>G, p.D350G Turkish F 0.75 Y Y Calcifications Maharaj (21) 30 c.1077del, p.G360Afs*49; c.1058A>G, p. K353R Unknown M 0.1 Y U Calcifications Zhao (10) 31 c.1079G>T, p.G360V
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Christine Rode Andreasen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Andreas Andersen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Filip Krag Knop in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD Trial . JAMA Neurology 2019 76 420 – 429 . ( https://doi.org/10.1001/jamaneurol.2018.4304 ) 70 GLP1R in Parkinson’s disease (GIPD
Search for other papers by Satoshi Higuchi in
Google Scholar
PubMed
Search for other papers by Hideki Ota in
Google Scholar
PubMed
Search for other papers by Takuya Ueda in
Google Scholar
PubMed
Search for other papers by Yuta Tezuka in
Google Scholar
PubMed
Search for other papers by Kei Omata in
Google Scholar
PubMed
Search for other papers by Yoshikiyo Ono in
Google Scholar
PubMed
Search for other papers by Ryo Morimoto in
Google Scholar
PubMed
Search for other papers by Masataka Kudo in
Google Scholar
PubMed
Division of Clinical Hypertension, Endocrinology and Metabolism, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
Search for other papers by Fumitoshi Satoh in
Google Scholar
PubMed
Search for other papers by Kei Takase in
Google Scholar
PubMed
MD Ugander M Gatehouse PD Arai AE Friedrich MG Neubauer S , et al . Myocardial T1-mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology
Search for other papers by Yao Ye in
Google Scholar
PubMed
Search for other papers by Aurelia Vattai in
Google Scholar
PubMed
Search for other papers by Nina Ditsch in
Google Scholar
PubMed
Search for other papers by Christina Kuhn in
Google Scholar
PubMed
Search for other papers by Martina Rahmeh in
Google Scholar
PubMed
Search for other papers by Sven Mahner in
Google Scholar
PubMed
Search for other papers by Myriam Ripphahn in
Google Scholar
PubMed
Search for other papers by Roland Immler in
Google Scholar
PubMed
Search for other papers by Markus Sperandio in
Google Scholar
PubMed
Search for other papers by Udo Jeschke in
Google Scholar
PubMed
Search for other papers by Viktoria von Schönfeldt in
Google Scholar
PubMed
Introduction Recurrent pregnancy losses (RPL) are defined as two or more consecutive failed pregnancies before the 20th week of pregnancy according to the Practice Committee of the American Society for Reproductive Medicine ( 1 ). RPL affects
Search for other papers by Benjamin Paul Green in
Google Scholar
PubMed
Search for other papers by Javier Thomas Gonzalez in
Google Scholar
PubMed
Search for other papers by Kevin Thomas in
Google Scholar
PubMed
Search for other papers by Emma Stevenson in
Google Scholar
PubMed
Search for other papers by Penny Louise Sheena Rumbold in
Google Scholar
PubMed
tract, pancreas, and adipose, act to influence the physiological mechanisms controlling energy regulation, eliciting divergent actions on feeding behaviour and metabolism (1) . In humans, hormonal peptides such as glucagon-like peptide-1 (GLP1) (2
Search for other papers by Emily Warmington in
Google Scholar
PubMed
Search for other papers by Gabrielle Smith in
Google Scholar
PubMed
Search for other papers by Vasileios Chortis in
Google Scholar
PubMed
Department of Neurosurgery, Technical University Munich (TMU), Munich, Germany
Search for other papers by Raimunde Liang in
Google Scholar
PubMed
Search for other papers by Juliane Lippert in
Google Scholar
PubMed
Search for other papers by Sonja Steinhauer in
Google Scholar
PubMed
Search for other papers by Laura-Sophie Landwehr in
Google Scholar
PubMed
Medizinische Klinik Und Poliklinik III, University Hospital Carl Gustav Carus, Dresden, Germany
Search for other papers by Constanze Hantel in
Google Scholar
PubMed
Search for other papers by Katja Kiseljak-Vassiliades in
Google Scholar
PubMed
Search for other papers by Margaret E Wierman in
Google Scholar
PubMed
Search for other papers by Barbara Altieri in
Google Scholar
PubMed
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Search for other papers by Paul A Foster in
Google Scholar
PubMed
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Search for other papers by Cristina L Ronchi in
Google Scholar
PubMed
.1634/theoncologist.2018-0838 ) 22 Awad MM Chu QS Gandhi L Stephenson JJ Govindan R Bradford DS Bonomi PD Ellison DM Eaton KD Fritsch H , et al. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with